Trials / Completed
CompletedNCT04653168
A Study of LY3041658 in Healthy Participants
A Single Dose, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Injections of LY3041658 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3041658 in healthy participants. The study will measure how the body absorbs, breaks down and gets rid of LY3041658.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3041658 | Administered SC |
Timeline
- Start date
- 2020-12-07
- Primary completion
- 2021-05-28
- Completion
- 2021-05-28
- First posted
- 2020-12-04
- Last updated
- 2021-06-18
Locations
1 site across 1 country: Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04653168. Inclusion in this directory is not an endorsement.